0001144204-06-049697.txt : 20061122 0001144204-06-049697.hdr.sgml : 20061122 20061122110216 ACCESSION NUMBER: 0001144204-06-049697 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20061122 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20061122 DATE AS OF CHANGE: 20061122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CELLEGY PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26372 FILM NUMBER: 061234868 BUSINESS ADDRESS: STREET 1: 1800 BYBERRY ROAD, BLDG. #13 CITY: HUNTINGDON VALLEY STATE: PA ZIP: 19006 BUSINESS PHONE: 2159140900 MAIL ADDRESS: STREET 1: 1800 BYBERRY ROAD, BLDG. #13 CITY: HUNTINGDON VALLEY STATE: PA ZIP: 19006 8-K 1 v058806_8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): November 22, 2006

Cellegy Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		0-26372		82-0429727
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)


2085B Quaker Pointe Drive Quakertown, Pennsylvania		18951
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (215) 529-6084

1800 Byberry Road, Building 13

Huntingdon Valley, PA 19006

(Former name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On November 22, 2006, Cellegy Pharmaceuticals, Inc. issued a press release announcing that at a special meeting of its stockholders held on November 22, 2006, the company’s stockholders approved the proposed sale to Strakan International Limited, a wholly owned subsidiary of ProStrakan Group plc, of Cellegy’s rights to Cellegesic™ (nitroglycerin ointment), which is branded Rectogesic outside of the United States, Fortigel™ (testosterone gel), Tostrex™ (testosterone gel), Tostran™ (testosterone gel), and Tostrelle® (testosterone gel), and related intellectual property assets. The press release stated that the closing of the asset sale transaction is expected to occur in the near future following completion of the other closing conditions.

Item 9.01 Financial Statements and Exhibits

Exhibit 99.1

Press Release dated November 22, 2006

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	CELLEGY PHARMACEUTICALS, INC.

Date: November 22, 2006	By:	/s/ Robert J. Caso
		Robert J. Caso Vice President, Finance (Duly Authorized Officer)

EX-99.1 2 v058806_ex99-1.htm

Cellegy Announces Stockholder Approval of

Asset Sale To ProStrakan

Sale Includes Rights to Cellegesic™, Fortigel™, Tostrex™, and Tostrelle®

Huntingdon Valley, PA - November 22, 2006 - Cellegy Pharmaceuticals, Inc. (OTC BB: CLGY.OB), a specialty pharmaceutical company, announced today that at a special meeting of its stockholders held on November 22, 2006, the company’s stockholders approved the proposed sale to Strakan International Limited, a wholly owned subsidiary of ProStrakan Group plc (LSE: PSK), a publicly-traded pharmaceutical company based in the United Kingdom, of Cellegy’s rights to Cellegesic™ (nitroglycerin ointment), which is branded Rectogesic outside of the United States, Fortigel™ (testosterone gel), Tostrex™ (testosterone gel), Tostran™ (testosterone gel) and Tostrelle® (testosterone gel), and related intellectual property assets, pursuant to an asset purchase agreement between the two companies originally announced on September 27, 2006. The closing of the asset sale transaction is expected to occur in the near future following completion of the other closing conditions.

About Cellegy

Cellegy Pharmaceuticals is a specialty biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women’s health care conditions, including sexual dysfunction, HIV prevention; and, gastrointestinal disorders. Savvy® (C31G vaginal gel), a novel microbicide gel product for contraception and the reduction in transmission of HIV in women, is currently undergoing Phase 3 clinical studies in the United States.

For more information contact:

Cellegy Pharmaceuticals, Inc.:
Richard C. Williams	Robert J. Caso
Chairman and Interim CEO	Vice President, Finance & CFO
(215) 529-6084	(215) 529-6084
www.cellegy.com